光针治疗阿片类药物使用障碍

注册号:

Registration number:

ChiCTR2200059497 

最近更新日期:

Date of Last Refreshed on:

2023-02-19 15:37:07 

注册时间:

Date of Registration:

2022-05-02 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

光针治疗阿片类药物使用障碍

Public title:

Light Needle for Opioid Use Disorder (OUD)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

光针治疗阿片类药物使用障碍的效果:随机对照试验

Scientific title:

Effect of Light Needle in the Treatment of Opioid Use Disorder: A Randomized Controlled Trial

研究课题代号(代码):

Study subject ID:

PMRPG8M0031

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

NCT05341219

申请注册联系人:

胡文龍 

研究负责人:

胡文龍 

Applicant:

Wenlong Hu 

Study leader:

Wenlong Hu 

申请注册联系人电话:

Applicant telephone:

+886 975 056815

研究负责人电话:

Study leader's
telephone:

+886 975 056815

申请注册联系人传真 :

Applicant Fax:

+886 7 7317123#2335

研究负责人传真:

Study leader's fax:

+886 7 7317123#2335

申请注册联系人电子邮件:

Applicant E-mail:

oolonghu@gmail.com

研究负责人电子邮件:

Study leader's E-mail:

oolonghu@gmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中國台灣高雄市鳥松區大埤路123號

研究负责人通讯地址:

中國台灣高雄市鳥松區大埤路123號

Applicant address:

123 Dapi Road, Niaosong District, Kaohsiung, Taiwan, China

Study leader's address:

123 Dapi Road, Niaosong District, Kaohsiung, Taiwan, China

申请注册联系人邮政编码:

Applicant postcode:

833

研究负责人邮政编码:

Study leader's postcode:

833

申请人所在单位:

高雄長庚紀念醫院中醫部

Applicant's institution:

Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital

研究负责人所在单位:

高雄長庚紀念醫院中醫部

Affiliation of the Leader:

Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

202200041A3

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

長庚醫療財團法人人體試驗倫理委員會

Name of the ethic committee:

Chang Gung Medical Foundation Institutional Review Board

伦理委员会批准日期:

Date of approved by ethic committee:

2022-03-18 00:00:00

伦理委员会联系人:

張正怡

Contact Name of the ethic committee:

Zhengyi Chang

伦理委员会联系地址:

中國台灣台北市敦化北路199號,

Contact Address of the ethic committee:

199 Tung Hua Road North, Taipei, Taiwan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+886 3 3196200

伦理委员会联系人邮箱:

Contact email of the ethic committee:

ccyi@cgmh.org.tw

研究实施负责(组长)单位:

高雄長庚紀念醫院

Primary sponsor:

Kaohsiung Chang Gung Memorial Hospital

研究实施负责(组长)单位地址:

中國台灣高雄市鳥松區大埤路123號

Primary sponsor's address:

123 Dapi Road, Niaosong District, Kaohsiung, Taiwan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

衛生福利部

Source(s) of funding:

Ministry of Health and Welfare (MOHW111-CMAP-M-113-112103)

研究疾病:

阿片类药物使用障碍  

Target disease:

Opioid Use Disorder

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探討光針輔助美沙冬治療阿片類藥物使用障礙患者的效果。  

Objectives of Study:

To investigate the effect of adjuvant light needle therapy in patients with opioid use disorder on methadone maintenance treatment.

药物成份或治疗方案详述:

背景:海洛因成癮仍然是全球性重大公共衛生問題之一,停止激動劑維持治療後再次使用海洛因很常見。 與使用阿片類藥物激動劑相關的問題意味著需要開發非阿片類藥物療法來改善急性和長期阿片類藥物戒斷綜合徵。 目的:探討光針輔助美沙冬治療阿片類藥物使用障礙患者的效果。 方法:從成癮戒治中心招募100名接受美沙冬維持治療的阿片類藥物使用障礙患者,隨機分配到實驗組或對照組。實驗組在4週內接受12次光針療法。對照組接受偽光針治療,沒有任何激光輸出。治療前後都會檢查尿液中的嗎啡含量,要求受試者報告他們在治療前後的前一周內使用海洛因的次數或天數,以及海洛因渴望/拒絕使用海洛因的 0-10 分視覺模擬量表評分,使用 Short Form-12v2 自評治療 4 週前後生活質量,記錄脈診以及計算治療前後的心率變異性。基線患者特徵將使用獨立 t 檢驗和卡方檢驗在實驗組和對照組之間進行比較,使用重複測量方差分析、廣義估計方程式和配對 t 檢驗比較兩組數據。 

Description for medicine or protocol of treatment in detail:

Background: Heroin addiction remains a significant public health problem worldwide, and relapse to heroin use following cessation of agonist maintenance treatment is common. The problems associated with use of opioid agonists mean that non-opioid therapies need to be developed to ameliorate acute and protracted opioid withdrawal syndromes. Objective: To investigate the effect of adjuvant light needle therapy in patients with opioid use disorder on methadone maintenance treatment. Methods: One hundred participants with opioid use disorder on methadone maintenance treatment will be enrolled from an addiction treatment center and randomly allocated to the experimental or control group. The experimental group is receiving 12 sessions of light needle therapy within 4 weeks. The control group is receiving sham light needle treatment, without any laser output. Urinary morphine levels are being checked before and after treatment. Subjects are requested to self-report their number of episodes or days of heroin use and 0–10-point visual analogue scale scores for heroin craving/refusal to use heroin during the previous week before and after treatment. Quality of life will be reported using the Short Form-12v2 before and after 4 weeks of treatment. Pulse diagnosis will be recorded and heart rate variability calculated before and after treatment. The baseline patient characteristics will be compared between the experimental and control groups using the independent t-test and chi-square test. Data are compared between the two groups using repeated-measures analysis of variance, generalized estimating equations, and the paired t-test. 

纳入标准:

Inclusion criteria

排除标准:

1. 有嚴重不穩定生理疾病;
2. 過去30天內接受過中醫藥(針灸)治療;
3. 主治醫師認為不適合參與者;
4. 未簽署書面受試者同意書。

Exclusion criteria:

1. Subjects with a critical illness;
2. Those who have taken Chinese herbs or received acupuncture treatment during the previous 30 days;
3. Those who are unsuitable for recruitment in the opinion of the attending physician;
4. Those who are unwilling to provide informed consent are excluded.

研究实施时间:

Study execute time:

From 2022-03-18 00:00:00 To 2024-02-14 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-04-19 00:00:00 To 2024-02-14 00:00:00

干预措施:

Interventions:

组别:

实验组

样本量:

50

Group:

Experimental group

Sample size:

干预措施:

光针疗法

干预措施代码:

Intervention:

light needle therapy

Intervention code:

组别:

对照组

样本量:

50

Group:

Control group

Sample size:

干预措施:

假光针疗法

干预措施代码:

Intervention:

sham light needle therapy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中國

省(直辖市):

台灣 

市(区县):

高雄 

Country:

China

Province:

Taiwan

City:

Kaohsiung

单位(医院):

高雄長庚紀念醫院 

单位级别:

三甲 

Institution
hospital:

Kaohsiung Chang Gung Memorial Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

尿吗啡水平

指标类型:

主要指标

Outcome:

urinary morphine levels

Type:

Primary indicator

测量时间点:

4周

测量方法:

Measure time point of outcome:

4 weeks

Measure method:

指标中文名:

上周使用海洛因的次数或天数

指标类型:

主要指标

Outcome:

times or days of heroin use during the previous week

Type:

Primary indicator

测量时间点:

4周

测量方法:

Measure time point of outcome:

4 weeks

Measure method:

指标中文名:

上周自我报告的海洛因渴望/拒绝使用海洛因的视觉模拟量表 (VAS) 分数(0-10 分)

指标类型:

次要指标

Outcome:

self-reported visual analogue scale (VAS) scores for heroin craving/refusal to use heroin (0-10 points) in the previous week

Type:

Secondary indicator

测量时间点:

4周

测量方法:

Measure time point of outcome:

4 weeks

Measure method:

指标中文名:

使用 Short Form-12v2 自我报告的生活质量

指标类型:

次要指标

Outcome:

self-reported quality of life using the Short Form-12v2

Type:

Secondary indicator

测量时间点:

4周

测量方法:

Measure time point of outcome:

4 weeks

Measure method:

指标中文名:

心率变异性

指标类型:

次要指标

Outcome:

heart rate variability

Type:

Secondary indicator

测量时间点:

4周

测量方法:

Measure time point of outcome:

4 weeks

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 70 years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

胡文龍使用生成随机序列的研究随机化器来选择區块大小为 4 且分配比例相等的随机置换块。

Randomization Procedure (please state who generates the random number sequence and by what method):

Wenlong Hu uses a research randomizer that generates the random sequence to select random permuted blocks with a block size of four and an equal allocation ratio.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

The trial participants, outcome assessors, and data analysts will be blinded after assignment to interventions using label A and B for the two groups.

Blinding:

The trial participants, outcome assessors, and data analysts will be blinded after assignment to interventions using label A and B for the two groups.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

可應要求提供

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Available on request

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

有關潛在參與者和已收案參與者的個人信息將被收集、共享和保存在一個獨立的壁櫥中,以在試驗之前、期間和之後確保機密性。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Personal information about potential and enrolled participants will be collected, shared, and maintained in an independent closet in order to protect confidentiality before, during, and after the trial.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2022-05-02 23:11:15